CURE Epilepsy
Meets Standards

Standards For Charity Accountability
Governance
-
Board Oversight
-
Board Size
-
Board Meetings
-
Board Compensation
-
Conflict of Interest
Measuring Effectiveness
-
Effectiveness Policy
-
Effectiveness Report
Finances
-
Program Expenses
-
Fundraising Expenses
-
Accumulating Funds
-
Audit Report
-
Detailed Expense Breakdown
-
Accurate Expense Reporting
-
Budget Plan
Fundraising & Info
-
Truthful Materials
-
Annual Report
-
Website Disclosures
-
Donor Privacy
-
Cause Marketing Disclosures
-
Complaints
CURE Epilepsy meets the 20 Standards for Charity Accountability.
Stated Purpose:
"to find a cure for epilepsy, by promoting and funding patient-focused research."
Year, State Incorporated:
1998, IL
Also Known As:
CURE: Citizens United for Research in Epilepsy
CURE Epilepsy is committed to funding patient-focused research to find a cure for epilepsy. The organization funds novel research projects that will hopefully accelerate research for a cure. Through an ambitious and innovative research program, the organization reports that it funds cutting-edge projects in 15 countries around the world.
For the year ended December 31, 2021, CURE Epilepsy's program expenses were:
Research: $4,070,075
Awareness: $962,652
Scholarship program: $50,000
Total Program Expenses: $5,082,727
Chief Executive
Beth Lewin Dean, Chief Executive Officer
Compensation*
$318,656
Chair of the Board
Kelly Cervantes
Chair's Profession / Business Affiliation
Board Size
13
Paid Staff Size
16
*2021 compensation includes annual salary and, if applicable, benefit plans, expense accounts, and other allowances.
Method(s) Used:
Direct mail appeals, Grant proposals, Internet, Direct mail appeals, Radio, Telemarketing, Print advertisements
Fundraising costs were 11% of related contributions. (Related contributions, which totaled $4,394,000, are donations received as a result of fundraising activities.)
This organization is tax-exempt under section 501(c)(3) of the Internal Revenue Code. It is eligible to receive contributions deductible as charitable donations for federal income tax purposes.
The following information is based on CURE Epilepsy's audited financial statements for the year ended December 31, 2021.
Source of Funds
Contributions | $2,430,452 |
Special events, net | $1,964,077 |
Federal grant revenue | $1,057,228 |
Grants returned | $262,718 |
Interest and dividends, net | $107,861 |
Gain on forgiveness of debt | $526,872 |
Total Income | $6,349,208 |
Programs: 86% Fundraising: 8% Administrative: 5%
Total Income | $6,349,208 |
Total expenses: | $5,884,336 |
Program expenses | $5,082,727 |
Fundraising expenses | $495,928 |
Administrative expenses | $305,681 |
Other expenses | $0 |
Income in Excess of Expenses | $464,872 |
Beginning Net Assets | $6,576,284 |
Other Changes In Net Assets | $330,583 |
Ending Net Assets | $7,371,739 |
Total Liabilities | $3,124,713 |
Total Assets | $10,496,452 |
Note 1: According to the organziation's audited financial statements for the year ended December 31, 2021, CURE received in-kind donations of $58,956 in the form of legal services.
Note 2: In the above financial section, "other changes in net assets" represents a change in fair value of investments.
An organization may change its practices at any time without notice. A copy of this report has been shared with the organization prior to publication. It is not intended to recommend or deprecate, and is furnished solely to assist you in exercising your own judgment. If the report is about a charity and states the charity meets or does not meet the Standards for Charity Accountability, it reflects the results of an evaluation of information and materials provided voluntarily by the charity. The name Better Business Bureau is a registered service mark of the International Association of Better Business Bureaus.
This report is not to be used for fundraising or promotional purposes.